Literature DB >> 21551321

Proteomic analysis yields an unexpected trans-acting point in control of the human sympathochromaffin phenotype.

Stéphane Chiron1, Zhiyun Wei, Yuqing Chen, Kuixing Zhang, Gen Wen, Wolfgang H Fischer, Sushil K Mahata, Daniel T O'Connor.   

Abstract

BACKGROUND: The secretory protein chromogranin A (CHGA) plays a necessary role in formation of catecholamine storage vesicles and gives rise to a catecholamine release-inhibitory fragment. Because genetic variation in the proximal human CHGA promoter predicts autonomic function and blood pressure, we explored how a common genetic variant alters transcription of the gene. METHODS AND
RESULTS: Bioinformatic analysis suggested that the common G-462A promoter variant (rs9658634) may disrupt as many as 3 transcriptional control motifs: LEF1, COUP-TF, and PPARγ-RXRα. During electrophoretic mobility shifts, chromaffin cell nuclear proteins bound specifically to the A (though not G) allele of CHGA promoter G-462A. On oligonucleotide affinity chromatography followed by electrospray ionization followed by 2-dimensional (tandem) mass spectrometry analysis of A allele eluates, the transcription factor LEF1 (lymphoid enhancer-binding factor-1) was identified. Interaction of LEF1 with the A allele at G-462A was confirmed by supershift. On cotransfection, LEF1 discriminated between the allelic variants, especially in chromaffin cells. Allele specificity of trans-activation by LEF1 was transferable to an isolated G-462A element fused to a heterologous (SV40) promoter. Because β-catenin (CTNNB1) can heterodimerize with LEF1, we tested the effect of cotransfection of this factor and again found A allele-specific perturbation of CHGA transcription.
CONCLUSIONS: Common genetic variation within the human CHGA promoter alters the interaction of specific factors in trans with the promoter, with LEF1 identified by proteomic analysis and confirmed by supershift. Coexpression experiments show functional effects of LEF1 and CTNNB1 on CHGA promoter. The findings document a novel role for components of the immune and WNT pathways in control of human sympathochromaffin phenotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551321      PMCID: PMC3319683          DOI: 10.1161/CIRCGENETICS.110.957886

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  54 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.

Authors:  K Masternak; E Barras; M Zufferey; B Conrad; G Corthals; R Aebersold; J C Sanchez; D F Hochstrasser; B Mach; W Reith
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

Review 3.  The Yin-Yang of TCF/beta-catenin signaling.

Authors:  N Barker; P J Morin; H Clevers
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

Review 4.  Chromogranin A. Storage and release in hypertension.

Authors:  M A Takiyyuddin; J H Cervenka; R J Hsiao; J A Barbosa; R J Parmer; D T O'Connor
Journal:  Hypertension       Date:  1990-03       Impact factor: 10.190

5.  Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues.

Authors:  Xijin Ge; Shogo Yamamoto; Shuichi Tsutsumi; Yutaka Midorikawa; Sigeo Ihara; San Ming Wang; Hiroyuki Aburatani
Journal:  Genomics       Date:  2005-08       Impact factor: 5.736

6.  Studies of the dysglycemic peptide, pancreastatin, using a human forearm model.

Authors:  Peter E Cadman; Fangwen Rao; Sushil K Mahata; Daniel T O'Connor
Journal:  Ann N Y Acad Sci       Date:  2002-10       Impact factor: 5.691

7.  Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin.

Authors:  E Porfiri; B Rubinfeld; I Albert; K Hovanes; M Waterman; P Polakis
Journal:  Oncogene       Date:  1997-12-04       Impact factor: 9.867

8.  Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Authors:  Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor
Journal:  Kidney Int       Date:  2008-04-23       Impact factor: 10.612

9.  Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion.

Authors:  Yuqing Chen; Fangwen Rao; Juan L Rodriguez-Flores; Manjula Mahata; Maple M Fung; Mats Stridsberg; Sucheta M Vaingankar; Gen Wen; Rany M Salem; Madhusudan Das; Myles G Cockburn; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Sushil K Mahata; Laurent Taupenot; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

10.  A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.

Authors:  Patricia L M Dahia; Ken N Ross; Matthew E Wright; César Y Hayashida; Sandro Santagata; Marta Barontini; Andrew L Kung; Gabriela Sanso; James F Powers; Arthur S Tischler; Richard Hodin; Shannon Heitritter; Francis Moore; Robert Dluhy; Julie Ann Sosa; I Tolgay Ocal; Diana E Benn; Deborah J Marsh; Bruce G Robinson; Katherine Schneider; Judy Garber; Seth M Arum; Márta Korbonits; Ashley Grossman; Pascal Pigny; Sérgio P A Toledo; Vania Nosé; Cheng Li; Charles D Stiles
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

View more
  1 in total

1.  A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders.

Authors:  Lakshmi Subramanian; Abrar A Khan; Prasanna K R Allu; Malapaka Kiranmayi; Bhavani S Sahu; Saurabh Sharma; Madhu Khullar; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2017-06-30       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.